title: High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers.
abstract: BACKGROUND
  The authors investigated the prevalence of hepatitis B virus (HBV) infection by using serologic markers in non-Hodgkin lymphoma (NHL) compared with other types of cancers in Chinese patients.
  
  
  METHODS
  In this case-control study, HBV and other hepatitis markers were compared between a study group and a control group. The study group included 587 patients with NHL (age range, 16-86 years), and the control group included 1237 patients (age range, 16-89 years) who were diagnosed with other cancers except liver cancer. An enzyme-linked immunosorbent assay was used to test serum samples from both groups for HBV markers and other hepatitis markers.
  
  
  RESULTS
  Logistic regression analysis showed that there was a higher prevalence of HBV infection in patients with the B-cell subtype of NHL (30.2%) than in patients with other cancers (14.8%; odds ratio [OR], 2.6; 95% confidence interval [95% CI], 2.0-3.4); however, in patients with the T-cell subtype of NHL, the HBV infection rate (19.8%) was similar to that among patients with other cancers (OR, 1.2; 95% CI, 0.8-1.8). A significant difference in HBV prevalence was found between B-cell and T-cell NHL (OR, 2.3; 95% CI, 1.4-3.6). In the patients with B-cell NHL, those who were infected with HBV had a significantly earlier disease onset (9.5 years) than those who were not infected with HBV. CONCLUSIONS.: The current results demonstrated that patients with B-cell NHL, but not patients with T-cell NHL, had a higher prevalence of HBV infection. HBV infection was associated with a significantly earlier disease onset (P < .001), a finding that suggested the possibility that HBV may play an etiologic role in the induction of B-cell NHL.
authors.affiliation: Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Guangzhou, People's Republic of China.
authors.forename: Feng
authors.initials: F
authors.lastname: Wang
authors.forename: Rui-Hua
authors.initials: RH
authors.lastname: Xu
authors.forename: Bing
authors.initials: B
authors.lastname: Han
authors.forename: Yan-Xia
authors.initials: YX
authors.lastname: Shi
authors.forename: Hui-Yan
authors.initials: HY
authors.lastname: Luo
authors.forename: Wen-Qi
authors.initials: WQ
authors.lastname: Jiang
authors.forename: Tong-Yu
authors.initials: TY
authors.lastname: Lin
authors.forename: Hui-Qiang
authors.initials: HQ
authors.lastname: Huang
authors.forename: Zhong-Jun
authors.initials: ZJ
authors.lastname: Xia
authors.forename: Zhong-Zhen
authors.initials: ZZ
authors.lastname: Guan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood; D016022:Case-Control Studies; D002681:China / Q000453:epidemiology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006509:Hepatitis B / Q000453:epidemiology*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000276:immunology / Q000302:isolation & purification*; D006801:Humans; D015994:Incidence; D016393:Lymphoma, B-Cell / Q000821:virology*; D016399:Lymphoma, T-Cell / Q000821:virology; D008297:Male; D008875:Middle Aged; D015995:Prevalence
chemical_list: D000914:Antibodies, Viral; D006514:Hepatitis B Surface Antigens